Haleon Plc (HLN.GB) Stock Price, Financials & Summary

Key data

Open—

From 52W high—

Volume—

Market cap—

P/E (TTM)—

P/S (TTM)—

Div yield—

Key data

Open

—

From 52W high

—

Volume

—

Market cap

—

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

P/E (TTM)

—

RSI (14)

—

MomentumView details →

1D Return

—

YTD Return

—

SummaryUpdated Jun 1, 2026

Haleon plc (LSE:HLN) is a British multinational consumer healthcare company that was spun off from GlaxoSmithKline in July 2022, making it one of the world's largest standalone consumer healthcare companies. The company was formed through the demerger of GSK's consumer healthcare division, which had been built over decades through acquisitions and internal development. Headquartered in Brentford, United Kingdom, Haleon operates globally across North America, Europe, Middle East, Africa, Latin America, and Asia Pacific, managing a portfolio of well-established consumer health brands that reach millions of consumers daily.

Ask drillr about Haleon Plc →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

—

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

—

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

—

ROA (TTM)

—

Asset Turnover

—

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

—

EBITDA YoY

—

MomentumView details →

1D Return

—

YTD Return

—

1Y Return

—

RSI (14)

—

vs 50D SMA

—

vs 200D SMA

—

Capital & dividendView details →

Debt/Equity

—

Current Ratio

—

Quick Ratio

—

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

19.38B

Net Income (TTM)

2.83B

Op. CF (TTM)

—

Latest newsMore news →

Haleon reported growing US sales of products targeting side-effects of weight-loss drugs, capitalizing on rising popularity of GLP-1 medications.4d ago

Haleon secured improved shelf placement agreements with U.S. retailers Walmart and Target to increase product visibility and market share.17d ago

Latest newsMore news →

Haleon reported growing US sales of products targeting side-effects of weight-loss drugs, capitalizing on rising popularity of GLP-1 medications.4d ago Haleon secured improved shelf placement agreements with U.S. retailers Walmart and Target to increase product visibility and market share.17d ago Haleon's antacid brand ENO launched a new advertising campaign in India, 'Acidity ke kayi naam, ENO sab par kare kaam', to educate consumers about acidity-related symptoms.35d ago